Background: Accumulating evidence suggests that c-kit-positive cells are present in the remodeled pulmonary vasculature bed of patients with pulmonary hypertension (PH). Whether stem cell factor (SCF)/c-kit-regulated pathways potentiate pulmonary vascular remodeling is unknown. Here, we tested the hypothesis that attenuated c-kit signaling would decrease chronic hypoxia-induced pulmonary vascular remodeling by decreasing pulmonary vascular cell mitogenesis. Methods: Neonatal FVB/NJ mice treated with nonimmune IgG (placebo), or c-kit neutralizing antibody (ACK2) as well as c-kit mutant mice (WBB6F1-Kit
n eonatal chronic hypoxia-induced pulmonary hypertension (PH) is characterized by vascular pruning and profound remodeling of peripheral pulmonary vessels (1) . These pulmonary vascular changes mimic those seen in infants with severe bronchopulmonary dysplasia and are a significant cause of morbidity and mortality. Currently, mechanistic pathways remain unclear and there are few efficacious therapies.
CD117 or c-kit, a tyrosine kinase receptor encoded at the W/Kit locus (2) , is mainly utilized as a stem cell marker (3, 4) .
Yet this receptor is also expressed on myocardial tissue, mast cells, dendritic cells, systemic vascular smooth muscle cells, epithelial cells, and fetal pulmonary vascular endothelial cells (2, (5) (6) (7) . The ligand for c-kit is stem cell factor (SCF). Encoded at the steel locus on murine chromosome 10, SCF is expressed by several cells, including endothelial cells and lung fibroblasts (8) . Interestingly, although recent studies have demonstrated increased c-kit pos cells in the media and adventitia of remodeled pulmonary arterioles, the role of SCF/c-kit signaling in the pathogenesis of PH is unclear (9) (10) (11) .
It is however known that binding of SCF to c-kit results in dimerization of the receptor, with subsequent activation of its intrinsic tyrosine kinase and phosphorylation of its tyrosine residues (12) . These phosphorylated sites are known to function as docking stations for several signal transduction proteins which induce the activation of signaling pathways, believed to be responsible for SCF/c-kit role in cell differentiation, survival, and proliferation (13, 14) . This latter process is particularly relevant in the context of PH as pulmonary vascular proliferation is one of the main mechanisms postulated to contribute to the pulmonary vascular remodeling evidenced in this disease.
Consistent with this theory, other investigators have suggested that c-kit and SCF play important roles in systemic vascular remodeling. The expression of c-kit and SCF were increased in atherosclerotic vessels (5) and mice with defective c-kit signaling (c-kit mutant mice) had decreased systemic vascular remodeling following injury (14, 15) . Moreover, administration of imatinib mesylate (a nonspecific c-kit antagonist) improved pulmonary vascular resistance as well as walking distance in idiopathic PH (16) .
This present study sought to test the hypothesis that activation of c-kit signaling potentiates neonatal chronic hypoxiainduced pulmonary vascular remodeling by increasing pulmonary vascular cell proliferation. Using a chronic hypoxia in vivo model of neonatal PH, we show that neonatal hypoxic c-kit mutant mice exhibit decreased PH, right ventricular hypertrophy (RVH), pulmonary vascular cell proliferation, and remodeling as compared to control hypoxic mice. In addition, we show that antagonism of c-kit attenuated neonatal chronic hypoxia-induced pulmonary vascular proliferation and remodeling. Further questioning to ascertain the mechanisms by which c-kit may participate in chronic hypoxia-induced pulmonary vascular remodeling revealed that SCF/c-kit signaling increased neonatal pulmonary vascular smooth muscle cell proliferation by augmenting extracellular signal-regulated protein kinase (ERK) 1/2 activation. These findings provide important insight into the involvement of SCF/c-kit signaling in the pathogenesis of PH.
RESULTS

SCF and c-kit Expression in Remodeled Pulmonary Arterioles of Mice With PH
We first sought to ascertain whether the expression of c-kit and its ligand, SCF, was increased in the pulmonary arterioles of neonatal FVB/NJ mice with chronic hypoxia-induced PH (Figure 1a-d) . Newborn FVB/NJ mice were exposed to 2 wk of normobaric normoxia or hypoxia. Following this exposure, pulmonary arterioles were dissected. There was a significant increase in the protein expression of c-kit (1.5-fold, P < 0.03), SCF (1.5-fold, P < 0.001), and phosphorylated c-kit (twofold, P < 0.002) in the pulmonary arterioles of mice with PH (Figure 1a-c) . Immunofluorescent staining revealed that c-kit was expressed on pulmonary vascular endothelial, medial, and adventitial cells (Figure 1d ).
Antagonism of SCF/c-kit Signaling Attenuates Pulmonary Vascular Remodeling
We next exposed neonatal mice to chronic hypoxia or normoxia from postnatal day 1-14 and then randomly assigned them to receive daily i.p. injections of a neutralizing c-kit antibody (ACK2) or placebo (PL) from postnatal day 7-14. As compared to normoxia, chronically hypoxic PL mice had a significant increase in right ventricular systolic pressure (RVSP; 15 ± 1 vs. 28 ± 4 mm Hg: room air (RA) vs. hypoxia-PL; P < 0.001), ratio of the weight of right ventricle to the left ventricle + septum (RV/LV + S; 0.3 ± 0.1 vs. 0.5 ± 0.1: RA vs. hypoxia-PL; P < 0.001), pulmonary vascular cell remodeling, and pulmonary vascular cell proliferation (Figure 2a-f) . In contrast, as compared to hypoxia-PL-treated mice, the administration of ACK2 to mice with PH decreased right ventricular RVSP (28 ± 4 vs. 21 ± 2 mm Hg: hypoxia-PL vs. hypoxia-ACK2; P < 0.02), RV/LV + S (0.5 ± 0.1 vs. 0.4 ± 0.1: hypoxia-PL vs. hypoxia-ACK2; P < 0.01), pulmonary vascular cell remodeling, and pulmonary vascular cell proliferation (Figure 2a-f) , suggesting that antagonism of SCF/c-kit signaling can attenuate PH.
Given that neonatal exposure to chronic hypoxia negatively impacts lung alveolarization, we evaluated the effect of ACK2 on lung alveolarization by measuring mean linear intercept. Normoxic mice which received ACK2 had a trend for worsened alveolarization, evidenced by increased mean linear intercept (36 ± 5 vs. 41 ± 5 µm: RA-PL vs. RA-ACK2; P < 0.06, n = 5/ group). Surprisingly, hypoxia-ACK2 mice had significantly lower mean linear intercept as compared to hypoxia-PL mice (49 ± 3 vs. 40 ± 6 µm: hypoxia-PL vs. hypoxia-ACK2; P < 0.03), suggesting that SCF/c-kit antagonism may improve alveolarization in neonatal hypoxic mice with PH (Figure 3a,b) . This improvement in lung alveolarization was however not accompanied by an increase in lung vascular density (6 ± 3 vs. 6 ± 1 vessels/high-power field: hypoxia-PL vs. hypoxia-ACK2; Figure 3c ). c-Kit Mutant Mice Have Decreased Susceptibility to Chronic Hypoxia-Induced PH Next, we questioned whether neonatal c-kit mutant mice would have decreased susceptibility to developing chronic hypoxia-induced PH. The c-kit mutant mice utilized in this study have the W-v mutation which is a missense mutation in the kinase domain of the c-kit coding sequence. During normoxia, there was no difference in RVSP, RVH, pulmonary vascular remodeling nor the pulmonary vascular proliferative index between the control and the mutant mice (Figure 4a-f) . Moreover, while exposure to chronic hypoxia resulted in a significant increase in RVSP (20 ± 1 vs. 30 ± 5 mm Hg: RA control vs. hypoxia control; P < 0.001), RV/LV + S, pulmonary vascular cell proliferation, and remodeling in the control mice, these changes were significantly attenuated in the c-kit mutant mice (Figure 4a- 
f).
Given evidence suggesting that chronic hypoxic exposure may increase extracellular signal-regulated protein kinase (ERK)-mediated signaling and that the latter may be important in hypoxia-induced pulmonary vascular cell proliferation (17,18), we questioned whether SCF/c-kit regulates pulmonary vascular cell proliferation by activating the ERK1/2 signaling pathway. As compared to normoxic mice, control mice exposed to chronic hypoxia had significantly increased expression of p-ERK1/2 (Figure 5a ). In contrast, p-ERK1/2 expression was unchanged in chronically hypoxic c-kit mutant mice (Figure 5a) . Similarly, while PL-treated hypoxic neonatal mice had an increase in ERK1/2 activation, administration of ACK2 to hypoxic mice decreased ERK1/2 activation (Figure 5b ). These findings suggest that c-kit may regulate pulmonary vascular cell proliferation by regulating ERK signaling.
SCF Increases Pulmonary Artery Smooth Muscle Cell Proliferation by ERK1/2 Pathway
In order to ascertain whether SCF/c-kit signaling modulates pulmonary artery smooth muscle (PASM) cell proliferation by activating the ERK1/2 pathway, we next evaluated whether a selective ERK1/2 antagonist, FR180204, could suppress SCFinduced PASM cell proliferation. PASM cells were isolated from neonatal mice and exposed to varying doses of SCF. We first demonstrated that unstimulated neonatal PASM cells do express c-kit (Figure 6a ) and exposure of PASM cells to 100 ng/ ml SCF not only increased the gene expression of c-kit ( Figure  6a ) but also caused an increase in p-ERK 1/2 expression Articles (Figure 6b ). These findings were accompanied by an increase in the percentage of Ki67 pos PASM cells (13.4 ± 3 vs. 50 ± 12%: SCF 0 ng/ml vs. SCF 100 ng/ml; P < 0.02), (Figure 6c,d ). Confirmatory findings with a BrdU Colorimetric Assay also demonstrated that PASM cells which were pretreated with vehicle and subsequently exposed to SCF 100 ng/ml had increased BrdU incorporation as compared to vehicle alone (Figure 6e ). In contrast, SCF-exposed PASM cells which were pretreated with the ERK1/2 antagonist had suppressed BrdU incorporation (Figure 6e) . Together, this suggests that SCF/ckit signaling may modulate PASM cell proliferation by regulating the ERK1/2 pathway.
DISCUSSION
The present study provides novel insight into the role of SCF/ckit signaling in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling. We show that the expression of SCF and c-kit are increased in the pulmonary arteries of neonatal mice with PH and furthermore that neonatal mice with defective c-kit signaling have decreased chronic hypoxia-induced pulmonary vascular remodeling and proliferation. In addition, we demonstrate that inhibition of SCF/ckit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling and decreases activation of the ERK1/2 pathway in PASM cells. Taken together, our present data not only demonstrates a mechanism by which SCF/c-kit signaling participates in chronic hypoxia-induced pulmonary vascular remodeling but it also provides a foundation to generate new therapies.
Prior pos cells in the pulmonary artery media of hypoxic calves and showed that these cells had highly augmented proliferative, migratory, invasive, and mitogenic capabilities (19) . In our Articles study, we demonstrate c-kit-positive cells in the endothelium, media, and adventitia of remodeled pulmonary vessels and western blot analysis of protein homogenates obtained from pulmonary arterioles demonstrated increased phosphorylated c-kit and SCF expression. This present finding is in keeping with prior data which demonstrated that hypoxia-inducible factor directly enhances the transcriptional activity of SCF and c-kit in response to hypoxia in tumor cell lines (20) . This hypoxia-induced enhanced c-kit and SCF expression is important in promoting angiogenesis following organ injury (21) and augmentation of SCF/c-kit signaling has been shown to improve organ repair by increasing angiogenesis (22) . Interestingly, we did not find a significant effect of SCF/c-kit signaling on pulmonary angiogenesis during hypoxia-induced PH. We however speculate that the increased c-kit expression noted in the pulmonary arteries of neonatal mice with chronic hypoxia-induced PH was an adaptive effect to increase perfusion to the pulmonary vascular wall and this response may have become maladaptive and promoted pulmonary vascular cell proliferation and remodeling. This is consistent with data published by Wang et al., who demonstrated significant SCFinduced proliferation of aortic vascular smooth muscle cells (15) and decreased proliferation of aortic smooth muscle cells following femoral artery wire injury in c-kit and SCF mutant mice.
In our present study, we also show that abrogation of SCF/c-kit signaling decreased pulmonary vascular cell proliferation and this was accompanied by decreased activation of the ERK1/2 pathway. This is intriguing as p42/p44 ERK, a member of the mitogen-activated protein kinase super family, has been previously shown to be upregulated in hypoxic lungs and to mediate pulmonary vascular cell proliferation (18) . Surprisingly, further questioning to elucidate the cellular population which had increased ERK1/2 activation revealed that isolated neonatal PASM cells express c-kit and they increased their proliferation and ERK1/2 activation following SCF stimulation. This was unexpected as other studies have not demonstrated c-kit expression on PASM cells, but rather their expression on native pulmonary vasculature cells was mainly restricted to endothelial cells (23) . It is possible that the variability in c-kit expression may be due to differences in the species studied as well as the developmental stage at the time of evaluation. Nonetheless, our finding is consistent with those of Davis et al. who also showed that c-kit is expressed on adult PASM cells (24) . 
Articles
Finally, it is important to mention the limitations of this study. c-Kit is present on several lung cells and thus its effects may not be localized to the pulmonary vascular bed. Indeed, studies in our laboratory have revealed an important role for c-kit in lung angiogenesis and alveolarization. Unexpectedly, in this present study, ACK2-treated hypoxic mice not only had an improvement in PH but they had better alveolar structure as compared to hypoxia-PL mice. Further studies will however be needed to delineate dose and temporal related effects as there was a trend towards a decrease in lung alveolarization and angiogenesis in the normoxic ACK2-treated mice. In addition, while the attenuation in pulmonary vascular remodeling evidenced following inhibition of SCF/c-kit signaling maybe potentially due to decreased ERK1/2 activation, we recognize that some of the PASM cells utilized in our in vitro studies may have been obtained from conduit vessels and their exact role in PH is unclear. We also acknowledge that some populations of c-kit-positive cells in the pulmonary vasculature are progenitor cells and these cells may potentiate vascular remodeling by either differentiating into myofibroblasts or secreting mitogenic factors. It is also possible that the reduction in RVH evidenced following c-kit antagonism was not entirely due to the improvement in PH but rather a direct effect of c-kit on myocardial mitogenesis.
Our present study however provides distinct and new evidence of the mechanistic role of SCF/c-kit signaling in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling. We demonstrate in vivo and in vitro the functional relevance of SCF/c-kit signaling in PH and we show that activation of SCF/c-kit signaling potentiates PASM cell proliferation and this is accompanied by ERK1/2 activation. We therefore speculate that future investigations evaluating novel strategies to inhibit SCF/c-kit receptor signaling may provide innovative therapies to attenuate chronic hypoxia-induced pulmonary vascular remodeling. or normoxia (RA; FiO 2 = 0.21) for 2 wk. In the second set of studies, FVB/NJ neonatal mice (1-2 d old; n = 26) were exposed to normobaric hypoxia (FiO 2 = 0.12) or normoxia (RA; FiO 2 = 0.21) for two wk. After 1 wk of this exposure, the mice were randomly assigned to receive daily i.p. injections of normal saline (PL; n = 15) or anti-c-kit antibody (ACK2; 50 µg/kg; n = 11) for 7 d, from postnatal day 7-14. The dose and frequency of dosing was based on a prior study (25) . The FiO 2 utilized in this neonatal study was based on previous studies which demonstrated increased mortality of the mice if lower FiO 2 or a longer duration of exposure were utilized (26) .
METHODS
Materials
Assessment of PH
RVSP was measured and continuously recorded on a Gould polygraph (model TA-400; Gould Instruments, Cleveland, OH) as previously described with minor modifications (27) . RVH was assessed by measuring the RV/LV + S.
Lung Morphometric Analysis
Lung perfusion was performed as previously described (28) . Serial paraffin-embedded lung sections 5 µm thick were stained with antibodies against α-α-smooth muscle actin (clone 1A4; Sigma-Aldrich) Figure 6 . SCF stimulates pulmonary artery smooth muscle (PASM) cell proliferation. (a) c-Kit mRNA expression in neonatal PASM cells exposed to varying doses of SCF. c-Kit transcripts were detected in unstimulated neonatal PASM cells and these transcripts increased following exposure to SCF 100 ng/ml (*P < 0.03: SCF 0 ng/ml vs. SCF 100 ng/ml; n = 4/group). (b) Increased p-ERK1/2 activation in PASM exposed to SCF 100 ng/ml (*P < 0.04: SCF 0 ng/ml vs. SCF 100 ng/ml; n = 4/group). p-ERK1/2 and T-ERK1/2 expression are normalized to β-actin. pos cells in neonatal PASM cells exposed to SCF 100 ng/ml (*P < 0.05: SCF 0 ng/ml vs. SCF 100 ng/ml; n = 4/group). (e) Neonatal PASM cells which were pretreated with vehicle and exposed to SCF 100 ng/ml had increased BrdU incorporation (*P < 0.007: DMSO vs. DMSO + SCF 100 ng/ml). Exposure of PASM to FR180204 alone suppressed BrdU incorporation (**P < 0.001: DMSO + SCF 100 ng/ml vs. FR180204). SCF-exposed PASM cells which were pretreated with the ERK1/2 antagonist had suppressed BrdU incorporation ( † P < 0.002: DMSO + SCF 100 ng/ml vs. FR180204 + SCF 100 ng/ml). DAPI, 4' ,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SMA, smooth muscle actin; SCF, stem cell factor. 
